GO TO ARTICLE OF INTEREST

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
The Lancet Oncology, 06/12/2013  Clinical Article

Pivot X et al. – After 3·5 years follow-up, we failed to show that 6 months of treatment with trastuzumab was non-inferior to 12 months of trastuzumab. Despite the higher rates of cardiac events, 12 months of adjuvant trastuzmab should remain the standard of care.
GO TO ARTICLES OF INTEREST
===================================================
AFTER FAILURE OF AVASTIN, THE TUMOR IS READY FOR MTOR INHIBITOR

Phase ii study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens
Clinical Cancer Research, 06/11/2013  Clinical Article

Ng K et al. – Everolimus 70 mg/week or 10 mg/day was well tolerated but did not confer meaningful efficacy in heavily pretreated mCRC patients.

GO TO ARTICLE
=====================================================
USEFUL TIPR FOR PRACTITIONER!

Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer
Clinical Cancer Research, 06/13/2013

Dennison JB et al. – Expression of LDHB predicted response to neoadjuvant chemotherapy within clinical subtypes independently of standard prognostic markers and PAM50 subtyping. These observations support prospective clinical evaluation of LDHB as a predictive marker of response for patients with breast cancer receiving neoadjuvant chemotherapy.

GO TO ARTICLE!
======================================= I AM GOING :HMMMMM, SOME RESEARCHER ARE STILL WORKING AT THIS NOW?

One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer
European Journal of Cancer, 06/13/2013  Clinical Article

Ejlertsen B et al. – CMF added to 1year of tamoxifen reduces the risk of a DFS event. The benefit from CMF was not significantly different in Luminal A and B subtypes.

GO TO ARTICLE!